Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Jul 01, 2011 9:42am
300 Views
Post# 18788197

RE:Any shrinkage in Shares Now Would do What

RE:Any shrinkage in Shares Now Would do What
Terry:

RE:"BRD is still well oversold and will be until it reaches the $2.50 to$2.75 range from which it should grow a lot more based on new reservefindings and solid management finally getting the attention we deserve."

[S] Despite the trading of Broker 79 (someone who should know has confirmed HFT of B79 and alleged psedo-liquidity). On the bright side; the major shareholders "may" get an "hint" of the Q2 numbers. Maybe maybe not? As we are still in the (multiple) transition zone (mainly to U/G and new contractors)  do we think that Q2 would be close to the median 17,250?

BWDIK? We need the two quarters. Explosives, Fuel & lubes seem to be stabilizing. Manpower will continue to be a challenge as training (aka stope school and costly contractors) and "raiding" from the far north operations will be the (ultimate/interim) solution.  Timmins is an expensive place to live but Matheson-BR & IF etc are more reasonable.

Happy Canada Day (excluding B79, yesterday's tape painters of course,for  painting a positive month end close) and Fourth of July to our Amex friends.

GLTAL- GLAP

Cheers
Stanley
Bullboard Posts